Blood Bags Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The global blood bags market covers single-use medical devices for blood collection, component separation, storage, and transfusion, serving blood banks, hospitals, and clinical laboratories. Valued at approximately $4.64 billion in 2025, the market operates within a landscape where roughly 118.5 million blood bags are collected globally each year based on World Health Organization data, underpinning an industry that supports more than 90 million annual blood transfusions worldwide. Blood bag design encompasses surface engineering and material composition that directly impacts product safety, bacterial biofilm resistance, and overall device performance in clinical settings.

• •Market valued at approximately $4.64 billion in 2025 with a projected annual growth rate of 3.41%
• •Approximately 118.5 million blood bags collected globally per year based on WHO statistical data
• •Over 90 million blood transfusions performed annually worldwide, sustaining consistent demand for collection and storage systems

Demand for blood bags is propelled by the global burden of chronic diseases, rising surgical volumes, trauma care expansion, and aging demographics, all of which require reliable blood supply chains. The impending regulatory ban on DEHP (di(2-ethylhexyl) phthalate) plasticizers in blood collection and storage bags across the EU and UK, set to take full effect by mid-2030, is accelerating product reformulation efforts, supply chain reassessment, and inventory transitions for manufacturers worldwide. Additional growth impetus comes from healthcare modernization in emerging economies, increasing prevalence of blood disorders, and the broadening adoption of component separation technologies that require multiple specialized bag configurations per donation.

• •EU and UK regulatory mandate phasing out DEHP-plasticized blood bags by July 2030, driving industry-wide reformulation to alternative plasticizers
• •Aging populations and rising surgical and trauma volumes increasing sustained global demand for blood collection and transfusion products
• •Growing healthcare infrastructure investment in emerging markets expanding access to blood banking systems

The blood bags market is segmented by product type, including single, double, triple, and quadruple blood bags, as well as specialized bags for leukocyte reduction and pathogen reduction, and by end user, primarily blood banks, hospitals, and diagnostic laboratories. Geographically, North America and Europe hold substantial market shares driven by advanced healthcare systems, strict regulatory oversight, and early adoption of non-DEHP bag technologies. The Asia-Pacific region is emerging as the fastest-growing market due to expanding healthcare infrastructure, large patient populations, and rising awareness of blood safety standards, while Latin America and the Middle East present incremental growth opportunities tied to healthcare modernization initiatives.

• •Product categories include single, double, triple, and quadruple blood bags, with specialized configurations for leukoreduction, pathogen inactivation, and component separation
• •North America and Europe dominate market share due to advanced healthcare infrastructure, strong regulatory frameworks, and early compliance with non-DEHP mandates
• •Asia-Pacific is the fastest-growing regional market, fueled by healthcare system expansion and increasing blood safety investment

What are the recent trends and outlook?

The market is experiencing a technology-driven transformation, with digital inventory management systems and machine learning increasingly deployed to optimize blood bank forecasting, reduce waste, and improve supply chain resilience. Next-generation blood bag designs are prioritizing non-DEHP alternative plasticizers, antimicrobial surface properties, and biofilm-resistant materials to meet evolving regulatory and safety standards. Looking ahead, the convergence of AI-driven supply chain optimization, sustainability-focused manufacturing practices, and ongoing compliance with global chemical safety mandates is expected to shape product innovation and competitive dynamics through 2030 and beyond.

• •AI-driven inventory forecasting and machine learning tools are being integrated into blood bank supply chains to improve stock management and reduce product waste
• •Regulatory deadlines for DEHP phase-out by mid-2030 are prompting industry-wide material science and manufacturing shifts toward alternative plasticizer technologies
• •Antimicrobial surface engineering and biofilm-resistant bag materials represent emerging product differentiation strategies for manufacturers